Artiva Biotherapeutics, Inc. (ARTV)
| Market Cap | 296.27M +322.6% |
| Revenue (ttm) | n/a |
| Net Income | -90.82M |
| EPS | -3.21 |
| Shares Out | 48.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 478,234 |
| Open | 5.93 |
| Previous Close | 5.91 |
| Day's Range | 5.85 - 6.16 |
| 52-Week Range | 2.75 - 14.53 |
| Beta | 2.41 |
| Analysts | Strong Buy |
| Price Target | 35.80 (+490.76%) |
| Est. Earnings | Nov 11, 2026 |
About ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/mic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ARTV stock is "Strong Buy." The 12-month stock price target is $35.8, which is an increase of 490.76% from the latest price.
News
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemi...
Artiva updates safety, translational data for AlloNK with rituximab
Artiva Biotherapeutics (ARTV) highlighted updated clinical, safety and translational data for AlloNK in combination with rituximab, presented by Guillermo Valenzuela, M.D., F.A.C.R., medical director ...
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
Artiva Biotherapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
A phase III NK cell therapy for refractory RA shows strong early efficacy and safety, with scalable manufacturing and outpatient administration. The FDA has agreed to a single pivotal trial, and the company is funded through 2029, supporting broad clinical and commercial plans.
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible ce...
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible ce...
Artiva Biotherapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing deep B-cell depletion and strong efficacy in early trials. Phase III is underway with robust funding, rapid community-based enrollment, and plans for broader autoimmune indications.
Artiva Biotherapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A novel NK cell platform is advancing in autoimmune disease, with a pivotal phase III trial in refractory RA targeting deep B-cell depletion and showing promising early efficacy and safety. The competitive landscape is favorable, and expansion into other indications is planned, with key data updates expected by year-end.
Artiva Biotherapeutics provides update on AlloNK data disclosures
Artiva Biotherapeutics (ARTV) provided an update on anticipated data disclosures and development milestones for its lead program, AlloNK, through year-end 2026. Artiva expects to disclose updated clin...
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2...
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible ce...
Artiva Biotherapeutics files $400M mixed securities shelf
17:27 EDT Artiva Biotherapeutics (ARTV) files $400M mixed securities shelf
Artiva Biotherapeutics reports Q2 EPS (63c), consensus (64c)
“The second quarter was transformative for Artiva. The clinical and translational data presented at EULAR reinforced AlloNK’s potential to drive deep B-cell depletion and meaningful clinical responses...
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive o...
Artiva Biotherapeutics Registration statement: Registration filing
Artiva Biotherapeutics filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Artiva Biotherapeutics Quarterly report: Q2 2026
Artiva Biotherapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Artiva Biotherapeutics Earnings release: Q2 2026
Artiva Biotherapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Artiva Biotherapeutics Proxy statement: Proxy filing
Artiva Biotherapeutics filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapi...
Artiva Biotherapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
AlloNK, a scalable allogeneic NK cell therapy, demonstrated high efficacy and safety in refractory RA, with 71% ACR50 rates and durable responses. A phase III trial will launch soon, targeting a large unmet market, with additional data and indications expected over the next two years.
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapi...
Artiva Biotherapeutics Transcript: Status update
AlloNK, a novel NK cell therapy, shows promising efficacy and durability in highly refractory RA and other autoimmune diseases, with a favorable safety profile and potential for first-in-class approval. A pivotal phase III trial is planned, supported by strong financial resources.
Artiva Biotherapeutics Press release: Status update
Artiva Biotherapeutics issued a press release on June 8, 2026, disclosing material business information to investors.
Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026
Artiva Biotherapeutics (ARTV) highlighted clinical, safety and translational data for AlloNK, also known as AB-101, an allogeneic, off-the-shelf, non-genetically modified natural killer cell therapy c...
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic scleros...